Analyses of the Gene Expression Omnibus public sequencing data indicated a lower level of MYBL2 mRNA in anti-PD-1 responders than in progressors with melanoma (GSE78220) (Supplemtary Fig. 5B). The gene discussed is MYBL2; the disease is melanoma.